Cargando…

Ruxolitinib Controls Lymphoproliferation and Diabetes in a STAT3-GOF Patient

Detalles Bibliográficos
Autores principales:	Wegehaupt, Oliver, Muckenhaupt, Tina, Johnson, Matthew B, Schwab, Karl Otfried, Speckmann, Carsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567728/ https://www.ncbi.nlm.nih.gov/pubmed/32944850 http://dx.doi.org/10.1007/s10875-020-00864-w

Ejemplares similares

Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient
por: Thalhammer, Julian, et al.
Publicado: (2021)

SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance?
por: Guisado Hernández, Paloma, et al.
Publicado: (2021)

Immunogenicity and Safety of COVID-19 mRNA Vaccine in STAT1 GOF Patients
por: Bloomfield, Marketa, et al.
Publicado: (2021)

HCV and Lymphoproliferation
por: Zignego, Anna Linda, et al.
Publicado: (2012)

Chronic mucocutaneous candidiasis, pancytopenia, and systemic mycosis in a patient with STAT1 gene mutation ineffectively treated with ruxolitinib
por: Bazan-Socha, Stanisława, et al.
Publicado: (2022)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

Ruxolitinib therapy and telomere length in myelofibrosis
por: Caocci, G, et al.
Publicado: (2016)

The Irrationality of GOF Avian Influenza Virus Research
por: Wain-Hobson, Simon
Publicado: (2014)

Epstein-Barr virus gastric ulcer associated with ruxolitinib
por: Kusano, Yoshiharu, et al.
Publicado: (2016)

Klebsiella pneumoniae primary liver abscess associated with ruxolitinib
por: Kusano, Yoshiharu, et al.
Publicado: (2016)

Ruxolitinib changes the natural course of myelofibrosis and its transplant outcome
por: Jung, Chul Won
Publicado: (2013)

Ruxolitinib-induced extreme thrombocytosis in a COVID-19 patient
por: Anguiano-Álvarez, Víctor Manuel, et al.
Publicado: (2021)

Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations—10 Children and Review of the Literature
por: Deyà-Martínez, Angela, et al.
Publicado: (2022)

GOF Mutant p53 in Cancers: A Therapeutic Challenge
por: Dolma, Lobsang, et al.
Publicado: (2022)

JAKi Salvage Therapy Followed by Curative Cord Blood Transplantation in a XIAP-Deficient Infant with Relapsing HLH
por: Maccari, Maria Elena, et al.
Publicado: (2023)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
por: Abdelmagid, Maymona G., et al.
Publicado: (2023)

Diffuse skin hyperpigmentation in CD30+ lymphoproliferation
por: Prka, Zeljko, et al.
Publicado: (2012)

COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib
por: Caradec, E., et al.
Publicado: (2021)

EBV reactivation mimicking a lymphoproliferative disorder associated with ruxolitinib therapy for myelofibrosis
por: Prem, Shruti, et al.
Publicado: (2019)

Defining Immune Engagement Thresholds for In Vivo Control of Virus-Driven Lymphoproliferation
por: Godinho-Silva, Cristina, et al.
Publicado: (2014)

Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target
por: Schulz-Heddergott, Ramona, et al.
Publicado: (2018)

Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
por: Ding, Kai, et al.
Publicado: (2023)

JC virus granule cell neuronopathy associated with Ruxolitinib: A case report and review of the literature
por: Nakayama, Kentaro, et al.
Publicado: (2020)

Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports
por: Gaspari, Valeria, et al.
Publicado: (2020)

Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice
Publicado: (1993)

Controversies on Rituximab Therapy in Sjögren Syndrome-Associated Lymphoproliferation
por: Quartuccio, Luca, et al.
Publicado: (2009)

The tumor microenvironment may trigger lymphoproliferation in cardiac myxoma
por: Jantuan, Eugeniu, et al.
Publicado: (2020)

Genetic heterogeneity of pediatric systemic lupus erythematosus with lymphoproliferation
por: Li, Guomin, et al.
Publicado: (2020)

Probiotic bacteria prevent Salmonella – induced suppression of lymphoproliferation in mice by an immunomodulatory mechanism
por: Wagner, R. Doug, et al.
Publicado: (2017)

Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?
por: Caocci, Giovanni, et al.
Publicado: (2020)

Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia
por: Niswander, Lisa M., et al.
Publicado: (2021)

Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches
por: Roszkowska, Katarzyna A., et al.
Publicado: (2022)

Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene
por: Helbig, Grzegorz, et al.
Publicado: (2017)

Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein–Barr virus
por: Jin, Zhili, et al.
Publicado: (2019)

Concomitant ruxolitinib with cytarabine-based induction chemotherapy in secondary acute myeloid leukemia evolving from myeloproliferative neoplasm
por: Kim, Dong Hyun, et al.
Publicado: (2023)

Detection of EBV in reactive and neoplastic lymphoproliferations in adults—when and how?
por: Stuhlmann-Laeisz, Christiane, et al.
Publicado: (2014)

PB2166: TET ENZYMES PROTECT AGAINST FATAL LYMPHOPROLIFERATION
por: Spoeck, S., et al.
Publicado: (2022)

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
por: Couban, Stephen, et al.
Publicado: (2018)

The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases
por: TÜRK, Can, et al.
Publicado: (2019)

Statistical power estimation dataset for external validation GoF tests on EVT distribution
por: Reghenzani, Federico, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_aiviqh98th949cnh6bn694uc7h